Bristol Myers Squibb 's beat-and-raise quarter wasn't enough to change our cautious view on the stock as we await updates on one of its promising drugs. Revenue in the third quarter, ended Sept. 30, rose 3% year over year to $12.2 billion, topping the consensus Street estimate of $11.8…